secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2022-10-19T23:59:59+00:00
Accession:  0001516551-22-000037
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye extends EHT deal outside date to Nov 15, receives $700K loan from EHT
--------------------------------------------------------------------------

- Third Amendment extends outside date for acquisition of Emerald Health Therapeutics to November 15, 2022, subject to possible 15-day extension.
- EHT loans Skye $700,000 at 12% interest (reduces to 5% upon deal closing), due earlier of Oct 17, 2023 or Dec 31, 2022 if deal terminated.
- Proceeds from loan to be used for general working capital; waiver obtained from Emerald Health Sciences for incurrence of debt.
- Stockholders and Supreme Court of British Columbia have approved the arrangement; closing expected early to mid-November.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000037/0001516551-22-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000037/skye-20221014.htm
  HTML page:      https://secwatch.observer/filing/0001516551-22-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer